First immediate-release PPI capsule approved
Specialty pharmaceutical company Santarus has received FDA approval for immediate-release proton pump inhibitor Zegerid. The new product contains omeprazole and sodium bicarbonate in 40 mg/1100 mg and 20 mg/1100 mg combinations.
First immediate-release PPI capsule approved
Specialty pharmaceutical company Santarus has received FDA approval for immediate-release proton pump inhibitor Zegerid. The new product contains omeprazole and sodium bicarbonate in 40 mg/1100 mg and 20 mg/1100 mg combinations. All previously available PPIs are delayed-release formulations that have an enteric coating that protects the drug from degradation by gastric acid, according to the company. The new capsules utilize sodium bicarbonate as a buffer that protects omeprazole from degradation without delaying absorption and initial acid suppression. Zegerid is approved for multiple indications, including the treatment of heartburn and other GERD-related symptoms; the short-term treatment of erosive esophagitis, active benign gastric ulcers, and active duodenal ulcers; and the maintenance of healing of erosive esophagitis. Dosing is once-daily on an empty stomach, at least one hour before a meal. Zegerid should be used with caution in patients on a sodium-restricted diet, as each capsule contains 1100 mg (13 mEq) of sodium. The drug is contraindicated in patients with metabolic alkalosis and hypocalcemia.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
